50% eGFR decline or end-stage kidney disease

1 paper1 finding

Humans1

Associations

1

SGLT2 inhibitors

downin humans1HR 0.49

1 study

SGLT2 inhibitors lower the risk of 50% eGFR decline or end-stage kidney disease in humans (HR 0.49, 95% CI 0.35-0.67).
Humanstype 2 diabetesmean 14.9 monthsn = 65,231
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
The lancet. Diabetes & endocrinology1 Jan 2020

More on SGLT2 inhibitors

Latest

The Lancet Diabetes & Endocrinology1 Jan

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Cohort study of 65,231 peopleSGLT2 inhibitors